Hybridize Therapeutics
PrivateLast Round
Strategic
Feb 9, 2022
Total Funding Raised
$315,000
Company Overview
Hybridize Therapeutics operates in Healthcare & Life Sciences and is based in Oegstgeest. Its latest recorded funding round was a Strategic round in February 2022.
Hybridize Therapeutics is a biotechnology company developing kidney-targeted RNA-based therapies for patients with acute and chronic kidney diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hybridize Therapeutics Comparables
Compare Hybridize Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Borealis Biosciences | 82% | |
| Judo Bio | 77% | |
| Asahi Kasei | 75% |
For institutional investors. Book with your work email.
Hybridize Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Feb 9, 2022 | ||||
| Accelerator | Jun 29, 2018 |
For institutional investors. Book with your work email.
Hybridize Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Mibiton Foundation | Debt |
| Netherlands Organization for Scientific Research | Debt |
| Life Sciences @ Work Venture Challenge | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 23, 2026
Monthly visitors grew 124% MoM, reaching 1.3K.
- Jan 20, 2026
Monthly visitors grew 41% MoM.
For institutional investors. Book with your work email.
Hybridize Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Hybridize Therapeutics's valuation, stock price, and market status.
Is Hybridize Therapeutics a public or private company?
Hybridize Therapeutics is a private company.
What is the current stock price of Hybridize Therapeutics?
Hybridize Therapeutics is a private company, so its shares have no public market price. Caplight tracks Hybridize Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Hybridize Therapeutics worth (valuation)?
Valuation information for Hybridize Therapeutics is not publicly available.
Can I buy Hybridize Therapeutics stock?
Hybridize Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Hybridize Therapeutics's last funding round?
Hybridize Therapeutics's most recent funding round was Strategic on February 9, 2022.
Who are the main investors in Hybridize Therapeutics?
Key investors in Hybridize Therapeutics include Mibiton Foundation, Netherlands Organization for Scientific Research, Life Sciences @ Work Venture Challenge.
Will Hybridize Therapeutics IPO soon?
No public IPO plans have been announced for Hybridize Therapeutics.
How can I track Hybridize Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Hybridize Therapeutics's shares on secondary markets.